Free Trial

Establishment Labs (ESTA) Stock Forecast & Price Target

Establishment Labs logo
$45.18 -0.76 (-1.65%)
(As of 01:10 PM ET)

Establishment Labs - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
4

Based on 5 Wall Street analysts who have issued ratings for Establishment Labs in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 1 has given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for ESTA.

Consensus Price Target

$60.60
34.13% Upside
According to the 5 analysts' twelve-month price targets for Establishment Labs, the average price target is $60.60. The highest price target for ESTA is $70.00, while the lowest price target for ESTA is $50.00. The average price target represents a forecasted upside of 34.13% from the current price of $45.18.
Get the Latest News and Ratings for ESTA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Establishment Labs and its competitors.

Sign Up

ESTA Analyst Ratings Over Time

TypeCurrent Forecast
12/31/23 to 12/30/24
1 Month Ago
12/1/23 to 11/30/24
3 Months Ago
10/2/23 to 10/1/24
1 Year Ago
12/31/22 to 12/31/23
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$60.60$60.60$57.60$74.67
Forecasted Upside34.13% Upside32.05% Upside42.01% Upside188.40% Upside
Consensus Rating
Buy
Moderate Buy
Moderate Buy
Buy

ESTA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ESTA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Establishment Labs Stock vs. The Competition

TypeEstablishment LabsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside31.91% Upside24,181.91% Upside14.07% Upside
News Sentiment Rating
Positive News

See Recent ESTA News
Positive News
Neutral News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/2/2024Stephens
4 of 5 stars
M. Carrico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
10/14/2024BTIG Research
2 of 5 stars
 Boost TargetBuy ➝ Buy$62.00 ➝ $65.00+56.02%
10/1/2024Citigroup
3 of 5 stars
 Boost TargetNeutral ➝ Neutral$45.00 ➝ $50.00+31.79%
8/7/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$61.00 ➝ $50.00+35.43%
6/6/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$65.00 ➝ $70.00+31.28%
11/9/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$95.00 ➝ $50.00+121.24%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:30 PM ET.


ESTA Forecast - Frequently Asked Questions

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Establishment Labs is $60.60, with a high forecast of $70.00 and a low forecast of $50.00.

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Establishment Labs in the last year. There is currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ESTA shares.

According to analysts, Establishment Labs's stock has a predicted upside of 34.13% based on their 12-month stock forecasts.

Over the previous 90 days, Establishment Labs's stock had 1 upgrade by analysts.

Establishment Labs has been rated by research analysts at BTIG Research, Citigroup, and Stephens in the past 90 days.

Analysts like Establishment Labs more than other "medical" companies. The consensus rating for Establishment Labs is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ESTA compares to other companies.


This page (NASDAQ:ESTA) was last updated on 12/30/2024 by MarketBeat.com Staff
From Our Partners